The IDH2 mutations typically lead to the neomorphic enzyme activity, resulting in the production of 2-HG. This metabolite inhibits alpha-ketoglutarate-dependent dioxygenases, leading to alterations in gene expression, impaired differentiation, and promotion of a cancerous state. The accumulation of 2-HG is considered an oncometabolite, contributing to the oncogenic process.
